Artificial Intelligence (AI) in Drug Discovery

Artificial Intelligence (AI) in Drug Discovery

Global Artificial Intelligence (AI) in Drug Discovery Market to Reach US$13.5 Billion by 2030

The global market for Artificial Intelligence (AI) in Drug Discovery estimated at US$2.6 Billion in the year 2023, is expected to reach US$13.5 Billion by 2030, growing at a CAGR of 26.4% over the analysis period 2023-2030. Oncology Therapeutic Area, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Neurodegenerative Diseases Therapeutic Area segment is estimated at 24.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$751.4 Million While China is Forecast to Grow at 25.7% CAGR

The Artificial Intelligence (AI) in Drug Discovery market in the U.S. is estimated at US$751.4 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 25.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 23.0% and 22.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 18.6% CAGR.

Global Artificial Intelligence (AI) in Drug Discovery Market - Key Trends and Drivers Summarized

How Is AI Revolutionizing the Drug Discovery Process?

Artificial intelligence is transforming the drug discovery process, bringing unprecedented speed, precision, and innovation to an area historically known for lengthy timelines and high costs. In traditional drug discovery, identifying potential compounds, testing them, and moving them through clinical trials can take over a decade and cost billions of dollars. AI is significantly shortening this process by using machine learning algorithms to analyze vast chemical datasets, identify promising drug candidates, and predict how these compounds will interact with specific biological targets. AI systems can screen millions of compounds in a fraction of the time it would take human researchers, narrowing down potential candidates with a high likelihood of success. For instance, deep learning models analyze molecular structures to predict properties such as toxicity, stability, and efficacy, streamlining the preclinical phase and reducing the risk of failure in later stages. By accelerating compound screening and enhancing predictive accuracy, AI is transforming early-stage drug discovery into a faster, more data-driven process, bringing new treatments to market sooner and expanding the scope of possible medical breakthroughs.

What Role Does AI Play in Personalized Medicine and Precision Therapeutics?

AI is opening new avenues for personalized medicine by enabling more accurate and tailored approaches to treatment development, considering individual genetic, environmental, and lifestyle factors. Through data from genomic sequencing and patient health records, AI algorithms can identify biomarkers and genetic variations that influence how individuals respond to specific treatments. This capability allows researchers to develop drugs that target particular patient populations, optimizing efficacy and minimizing side effects. AI-driven predictive models also enable more precise dose optimization, adjusting for factors like age, weight, and metabolic rate, which is especially critical in treating diseases such as cancer, where patient responses to treatment can vary significantly. Additionally, AI in drug discovery supports the identification of novel drug targets linked to rare genetic conditions or complex diseases, such as Alzheimer’s, that may not have been evident using traditional methods. By transforming vast amounts of biological data into actionable insights, AI is paving the way for precision therapeutics, where treatments can be tailored to the specific needs of individual patients, thus enhancing outcomes and reducing trial-and-error in treatment approaches.

How Does AI Enhance Efficiency in Clinical Trials?

AI is optimizing clinical trials by streamlining participant selection, improving monitoring, and predicting trial outcomes, thus addressing some of the biggest hurdles in the drug discovery process. Patient recruitment, a time-consuming and costly aspect of clinical trials, is being transformed through AI algorithms that analyze electronic health records to identify eligible participants based on genetic markers, demographics, and medical history, ensuring more precise matches for trial criteria. This approach reduces recruitment time and improves the likelihood of enrolling participants who are more likely to respond favorably to the drug being tested. During the trial, AI-powered data analytics and wearable devices provide real-time monitoring, tracking vital signs, adherence, and adverse effects, offering comprehensive insights into patient responses. Predictive analytics further enhance trial efficiency by forecasting potential trial outcomes based on historical data, guiding decisions about trial continuation or modification to optimize resource allocation. AI’s role in trial simulation models is also proving valuable, as it helps researchers predict the success rate and adjust protocols, ultimately reducing the time and costs associated with clinical trials. Through these innovations, AI is improving the reliability and speed of clinical trials, facilitating a more agile and responsive drug discovery process.

What Factors Are Driving the Growth of AI in the Drug Discovery Market?

The growth in the AI in drug discovery market is driven by several factors, including technological advancements, the increasing need for cost-effective and efficient drug development, and the rise of complex diseases requiring innovative treatment approaches. One significant driver is the advancement of computational power and cloud-based platforms, which allow for the analysis of large datasets, complex molecule structures, and high-throughput screening, making AI more accessible and scalable for pharmaceutical companies. Additionally, the soaring costs and long timelines associated with traditional drug discovery are prompting the industry to adopt AI-driven approaches that reduce both time and expenditure, as AI offers tools to identify promising compounds and predict outcomes with higher efficiency. The rise of personalized medicine and targeted therapies has created demand for AI solutions capable of analyzing genetic and biomarker data to tailor treatments to specific patient profiles. Moreover, the increasing prevalence of complex diseases like cancer and neurodegenerative disorders has accelerated the need for novel drug discovery methods, as traditional approaches have struggled to address these challenges adequately. Finally, regulatory support for AI applications in drug discovery has also contributed to market growth, as governments and health organizations are beginning to acknowledge and facilitate the role of AI in addressing urgent medical needs. Together, these technological, economic, and healthcare demands are driving the integration of AI into drug discovery, setting the stage for a future where AI significantly enhances the pace and precision of bringing new medicines to market.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence (AI) in Drug Discovery market in terms of US$ Thousand by the following Application; Therapeutic Area, and Geographic Regions/Countries:

Segments:
Therapeutic Area (Oncology, Neurodegenerative Diseases, Metabolic Diseases, Cardiovascular Disease, Infectious Disease, Other Therapeutic Areas); Application (Drug Optimization & Repurposing, Preclinical Testing, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 293 Featured) -

• Atomwise, Inc.
• Benevolentai
• Berg LLC
• Bioage
• Cloud Pharmaceuticals, Inc.
• Cyclica
• Deep Genomics
• Envisagenics
• Exscientia
• Google (A Subsidiary of Alphabet Inc.)
• IBM Corporation
• Insilico Medicine
• Microsoft Corporation
• Numedii, Inc.
• Numerate
• NVIDIA Corporation
• Owkin, Inc.
• Twoxar, Incorporated
• Verge Genomics
• Xtalpi, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.